Open Access1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting
Author(s) -
AB Fernández Román,
C Bravo Lázaro,
J Letéllez Fernández,
N Herrero Muñoz,
A Andrés Rosado,
Christian López,
MDM García Gutiérrez,
Magdalena Gil
Publication year - 2018
Publication title -
pubmed central
Language(s) - English
Resource type - Conference proceedings
DOI - 10.1136/ejhpharm-2018-eahpconf.5
Subject(s) - docetaxel , nivolumab , medicine , lung cancer , oncology , cancer , immunotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom